Sertraline in the treatment of depression in the elderly

Aging Health

Volumn 2, Issue 2, 2006, Pages 199-208

  McClintock, Shawn M ^a   Queenan, Kip ^a   Faniran, Olayemi ^a   Ranginwala, Najeeb ^a   Husain, Mustafa M ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Geriatric depression; Major depressive disorder; Selective serotonin reuptake inhibitors; Sertraline

Indexed keywords

ALCOHOL; ANTIARRHYTHMIC AGENT; CARBAMAZEPINE; CIMETIDINE; CITALOPRAM; DIGOXIN; ESCITALOPRAM; FLUOXETINE; IMIPRAMINE; KETONE; MONOAMINE OXIDASE INHIBITOR; NORTRIPTYLINE; PAROXETINE; PLACEBO; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TERFENADINE; TRICYCLIC ANTIDEPRESSANT AGENT; WARFARIN;

AGED; AGITATION; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG USE; DYSPEPSIA; DYSPHORIA; EJACULATION DISORDER; ELDERLY CARE; FATIGUE; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; HYPOGLYCEMIA; HYPONATREMIA; INSOMNIA; LIBIDO DISORDER; MAJOR DEPRESSION; NAUSEA; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PANIC; PHARMACODYNAMICS; POSTTRAUMATIC STRESS DISORDER; PRESCRIPTION; SIDE EFFECT; SOCIAL PHOBIA; SOMNOLENCE; STEADY STATE; SWEATING; TACHYCARDIA; TREMOR; XEROSTOMIA;

EID: 33646568097     PISSN: 1745509X     EISSN: 17455103     Source Type: Journal    
DOI: 10.2217/1745509X.2.2.199     Document Type: Article

References (61)

1. Lebowitz BD, Pearson JL. Schneider LS et al.: Diagnosis and treatment of depression in late life: consensus statement update. JAMA 278, 1186-1190 (1997).
2. Blazer DG, Bachar JR, Manton KG: The epidemiology of depression in an elderly community population. Gerontologist 27, 281-287 (1987).
3. Broadhead EW, Blazer DG, George LK: Depression, disability days, and days lost from work in a prospective epidemiologic survey. JAMA 264, 2524-2528 (1990).
4. Kasper S, de Swart H, Andersen HF: Escitalopram in the treatment of depressed elderly patients. Am. J. Geriatr. Psychiatry 13, 884-891 (2005).
5. Husain MM, Rush AJ, Sackeim HA et al.: Age-related characteristics of depression: a preliminary STAR*D Report. Am. J. Geriatr. Psychiatry 13, 852-860 (2005).
6. Gaynes BN, West SL, Ford CA et al.: Screening for suicide risk in adults: a summary of the evidence for the U.S. Preventive Services Task Force. Ann. Intern. Med. 140(10), 822-835 (2004).
7. Loebel JP: Completed suicide in late life. Psychiatric Serv. 56(3), 260-262 (2005).
8. Barak Y, Olmer A, Aizenberg D: Antidepressants reduce the risk of suicide among elderly depressed patients. Neuropsychopharmacology 31(1), 178-181 (2005).
9. Rush AJ, Fava M, Wisniewski SR et al., for the STAR*D Investigators Group: Sequenced Treatment Alternatives to Relieve Depression (STAR*D): rationale and design. Control. Clin. Trials 25, 119-142 (2004).
10. Alexopoulos GS, Katz IR, Reynolds CF III et al.: The expert consensus guideline series: pharmacotherapy of depressive disorders in older patients. Postgrad. Med. Special Rep. 110, 1-86 (2001).
11. Colenda C, Wagenaar DB, Mickus M et al.: Comparing clinical practice with guideline recommendations for the treatment of depression in geriatric patients. Am. J. Geriatr. Psychiatry 11, 448-457 (2003).
12. Offson M, Marcus SC, Druss B et al.: National trends in outpatient treatment of depression. JAMA 287, 203-209 (2002).
13. Whooley MA, Stone B, Soghikian K: Randomized trial of case-finding for depression in elderly primary care patients. J. Gen. Intern. Med. 15(5), 293-300 (2000).
14. Solai LK, Mulsant BH, Pollock BG: Selective serotonin reuptake inhibitors for late-life depression: a comparative review. Drup Aging 18 (5), 355-368 (2001).
15. Mamdani MM. Parikh SV, Austin PC et al.: Use of antidepressants among elderly subjects: trends and contributing factors. Am. J. Psychiatry 157(3), 360-367 (2000).
16. Preskorn SH: Reproducibility of the in vivo effect of the selective serotonin reuptake inhibitors on the in vivo function of cytochrome P450 2D6: an update. J. Psychiatr. Pract. 9(3), 228-236 (2003).
17. Hiemke C, Hartter S: Pharmacokinetics of selective serotonin reuptake inhibitors. Phamacol. Ther. 85, 11-28 (2000).
18. MacQueen G, Born L, Steiner M: The selective serotonin reuptake inhibitor sertraline: its profile and use in psychiatric disorders. CNS Drug Rev 7(1),1-24 (2001).
19. Zoloft® [sertraline hydrochloride] US package insert. Pfizer Inc., NY, USA (2005).
20. Muijsers RB, Plosker GL, Noble S: Sertraline: a review of its use in the management of major depressive disorder in elderly patients. Drugs Aging 19(5), 377-392 (2002).
21. Ronfield RA. Tremaine LM, Wilner KD: Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers. Clin. Pharmacokinet. 32(Suppl. 1), 22-30 (1997).
22. Murdoch D, McTavish D: Sertraline: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive-compulsive disorder. Drugs 44, 604-624 (1992).
23. Perry CM. Benfield P: Sertraline: an overview of its pharmacological properties and a review of its therapeutic efficacy in obsessive-compulsive disorder. CNS Drugs 7, 480-500 (1997).
24. Goodnick PJ, Goldstein BJ: Selective serotonin reuptake inhibitors in affective disorders - I. Basic pharmacology. J. Psychopharmacol. 12(Suppl. B), S5-S20 (1998).
25. DeVane CL, Liston HL, Markowitz JS: Clinical pharmacokinetics of sertraline. Clin. Pharmacokinet. 41(15), 1247-1266 (2002).
26. Ronfield RA, Wilner KD, Baris BA: Sertraline. Chronopharmacokinetics and the effect of co-administration with food. Clin. Pharmacokinet. 32(Suppl. 1), 50-55 (1997).
27. Warrington SJ: Clinical implications of the pharmacology of sertraline. Int. Clin. Psychopharmacol. 6(Suppl. 2), 11-21 (1991).
28. Witner KD, Baris BA, Foulds GH: Multiple dose pharmacokinetics of sertraline in subjects with varying degrees of renal impairment. Eur: Neuropsychopharmacol. 6(Suppl. 3), 41 (1996).
29. Demolis JL, Angebaud P, Grange JD et al.: Influence of liver cirrhosis on sertraline pharmacokinetics. Br. J. Clin. Pharmacol. 42, 394-397 (1996).
30. Preskorn SH, Alderman J. Greenblatt DJ. Horst WD: Sertaline does not inhibit cytochrome (P450) 3A-mediated drug metabolism in vivo. Psychopharmacol. Bull. 33, 659-665 (1997).
31. Rapeport WG, Williams SA, Muirhead DC et al.: Absence of a sertraline-mediated effect on the pharmacokinetics and pharmacodynamics of carbamazepine. J. Clin. Psychiatry 57(Suppl. 1), 20-23 (1996).
32. Obach RS, Cox LM, Tremaine LM: Sertraline metabolized by multiple cytochrome P450 enzymes, monoamine oxidases. and glucuronyl transferases in human: an in vitro study. Drug Metab. Dispos. 33(2), 262-270 (2005).
33. Apseloff G, Wilner KD, Gerber N. Tremaine LM: Effect of sertraline on protein binding of warfarin. Clin. Pharmacokinet. 32(Suppl. 1), 37-42 (1997).
34. Schneider LS. Nelson JC, Clary CM et al.: An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression. Am. J. Psychiatry 160, 1277-1285 (2003).
35. Hamilton M: A rating scale for depression. J. Neurol. Neurasurg. Psychiatr. 23, 56-62 (1960).
36. Guy W: Assessment Manual for Psychopharmacology, US Government Printing Office, Washington, DC, USA (1976).
37. Bondareff W, Alpert M, Friedhoff A et al.: Comparison of sertraline and nortriptyline in the treatment of major depressive disorder in late life. Am. J. Psychiatry 157, 729-736 (2000).
38. Forlenza OV, Almeida OP, Stoppe A Jr et al.: Antidepressant efficacy and safety of low-dose sertraline and standard-dose imipramine for the treatment of depression in older adults: results from a double-blind, randomized, controlled clinical trial. Int. Psychogeriatr. 13(1), 75-84 (2001).
39. Davidson J, Turnbull CD, Strickland R et al.: The Montgomery-Asberg Depression Scale: reliability and validity. Acta Psychiatr. Scand. 73(5), 544-548 (1986).
40. Folstein MF, Folstein SE, McHugh PR: "Mini-Mental State" a practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12, 189-198 (1975).
41. Newhouse PA, Krishnan KRR, Doraiswamy PM et al.: A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients. J. Clin. Psychiatry 6l, 559-568 (2000).
42. Rocca P, Calvarese P, Faggianno F et al.: Citalopram versus sertraline in late-life nonmajor clinically significant depression: a 1 -year follow-up clinical trial. J. Clin. Psychiatry 66(3), 360-369 (2005).
43. Sheikh JI, Cassidy EL, Doraiswamy PM et al.: Efficacy, safety, and tolerability of sertraline in patients with late-life depression and comorbid medical illness. J. Am. Geriatr. Soc. 52, 86-92 (2004).
44. Krishnan KR, Doraiswamy PM, Clary CM: Clinical and treatment response characteristics of late-life depression associated with vascular disease: a pooled analysis of two multicenter trials with sertraline. Prog. Neuropsychopharmacol. Biol. Psychiatry 25(2), 347-361 (2000).
45. Lykestos CG, Sheppard JM, Steele CD et al.: Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease: initial results from the Depression in Alzheimer's Disease study. Am. J. Psychiatry 157 (10), 1686-1689 (2000).
46. Loewe B, Schenkel I, Bair MJ et al.: Efficacy, predictors of therapy response, and safety of sertraline in routine clinical practice: prospective, open-label, non-interventional postmarketing surveillance study in 1878 patients. J. Affect. Disord. 87, 271-279 (2005).
47. Newhouse PA: Use of serotonin selective reuptake inhibitors in geriatric depression. J. Clin. Psychiatry 57(Suppl. 5), 12-22 (1996).
48. Thompson C, Lane R, Wiseman R: Safety and efficacy of sertraline in elderly versus young depressed patients in primary care. Neuropsychopharmacology 10, S106 (1994).
49. Wilson K, Berti C, Whitehead A: The efficacy of sertraline in elderly patients suffering from major depression. Biol. Pychiatry, 42, S242 (1997).
50. Arranz FJ, Ros S: Effects of comorbidity and polypharmacy on the clinical usefulness of sertraline in elderly depressed patients: an open multicentre study. J. Affect. Disord. 46, 285-291 (1997).
51. Kirby D, Ames D: Hyponatraemia and selective serotonin re-uptake inhibitors in elderly patients. Int. J. Geriatr. Psychiatry 16(5), 484-493 (2001).
52. Pollak PT, Mukherjee SD, Fraser AD: Sertraline-induced hypoglycemia. Ann. Pharmacother. 35(11). 1371-1374 (2001).
53. Caracci G: Unsuccessful suicide attempt by sertraline overdose. Am. J. Psychiatry 151, 147(1994).
54. Doogan DP: Toleration and safety of sertraline: experience worldwide. Int. Clin. Psychopharmacol. 6(Suppl. 2), 47-56 (1991).
55. Louie AK, Lannon RA, Ajari LJ: Withdrawal reaction after sertratine discontinuation. Am. J. Psychiatry 151, 450-451 (1994).
56. Lejoyeux M, Ades J: Antidepressant discontinuation: a review of the literature. J. Clin. Pyschiatry 58 (Suppl. 7), 11-15 (1997).
57. Graber MA, Hoehns TB, Perry PJ: Sertraline-phenelzine drug-interaction: a serotonin syndrome reaction. Ann. Pharmacother. 28, 732-735 (1994).
58. Wilson KC, Mottram PG, Ashworth L et al.: Older community residents with depression: long-term treatment with sertraline. Br. J. Psychiatry. 182, 492-497 (2003).
59. Oslin DW, Ten Have TR, Streim JE et al.: Probing the safety of medications in the frail elderly: evidence from a randomized clinical trial of sertraline and venlafaxine in depressed nursing home residents. J. Clin. Psychiatry 64, 875-882 (2003).
60. Oslin DW, Streim JE, Katz IR et al.: Heuristic comparison of sertraline with nortriptyline for the treatment of depression in frail elderly patients. Am. J. Geriatr. Psychiatry 8, 141-149 (2000).
61. Devanand DP, Pelton GH, Marston K et al.: Sertraline treatment of elderly patients with depression and cognitive impairment. Int. J. Geriatr. Psychiatry 18, 123-130 (2003).